

LFIR # 3049

Phase III: Expansion of Excellent and Equitable Sickle Cell Disease Care in Florida

2. Senate Sponsor Darryl Rouson

3. Date of Request 12/19/2023

4. Project/Program Description

To continue operational support and medically and holistically care for people affected by Sickle Cell Disease in Florida that remain afflicted with low access to treatment and low quality of life. With the support of previous appropriations funding, we have established ourselves as the single-point center satellite site in major cities in the State of Florida. We need funding to continue supporting these locations operations and offerings for patients.

5. State Agency to receive requested funds

Department of Health

State Agency contacted? Yes

6. Amount of the Nonrecurring Request for Fiscal Year 2024-2025

Type of Funding	Amount
Operations	2,000,000
Fixed Capital Outlay	0
Total State Funds Requested	2,000,000

7. Total Project Cost for Fiscal Year 2024-2025 (including matching funds available for this project)

Type of Funding	Amount	Percentage	
Total State Funds Requested (from question #6)	2,000,000	100%	
Matching Funds			
Federal	0	0%	
State (excluding the amount of this request)	0	0%	
Local	0	0%	
Other	0	0%	
Total Project Costs for Fiscal Year 2024-2025	2,000,000	100%	

8. Has this project previously received state funding? Yes

Fiscal Year	Amo	ount	Specific	Vetoed
(уууу-уу)	Recurring	Nonrecurring	Appropriation #	
2023-24	0	5,000,000	483	No

9. Is future funding likely to be requested?

a. If yes, indicate nonrecurring amount per year.

b. Describe the source of funding that can be used in lieu of state funding.

10. Has the entity requesting this project received any federal assistance related to the COVID-19 pandemic?

No

No



If yes, indicate the amount of funds received and what the funds were used for.

Complete questions 11 and 12 for Fixed Capital Outlay Projects

11. Status of Construction

a. What is the current phase of the project?

O Planning

Construction

b. Is the project "shovel ready" (i.e permitted)?

O Design

c. What is the estimated start date of construction?

- d. What is the estimated completion date of construction?
- 12. List the owners of the facility to receive, directly or indirectly, any fixed capital outlay funding. Include the relationship between the owners of the facility and the entity.

🔘 N/A

13. Details on how the requested state funds will be expended

Spending Category	Description	Amount		
Administrative Costs:				
Executive Director/Project Head Salary and Benefits	Responsible for the oversight of overall management of the project.	150,000		
Other Salary and Benefits	Grants and finance administrators are responsible to provide financial and administrative support services to designated program staff, assist with oversight of implementation and monitoring.	50,000		
Expense/Equipment/Travel/Supplies/ Other		0		
Consultants/Contracted Services/Study		0		
Operational Costs: Other				
Salary and Benefits	Clinical staff, technicians, programmers, laboratory assistants to carry out the project in each service area	300,000		
Expense/Equipment/Travel/Supplies/ Other	Other operational expenses include santization and cleaning services, utilities, equipment to carry out the project functions, staff travel, training	1,500,000		
Consultants/Contracted Services/Study		0		
Fixed Capital Construction/Major Renovation:				
Construction/Renovation/Land/ Planning Engineering		0		
Total State Funds Requested (m	ust equal total from question #6)	2,000,000		

14. Program Performance

a. What specific purpose or goal will be achieved by the funds requested?



To continue operational support and medically and holistically care for people affected by Sickle Cell Disease in Florida that remain afflicted with low access to treatment and low quality of life. With the support of previous appropriations funding, we have established ourselves as the single-point center satellite site in major cities in the State of Florida. We need funding to continue supporting these locations operations and offerings for patients.

b. What activities and services will be provided to meet the intended purpose of these funds?

Patient assessment, disease management, connecting patients to providers to care through direct in-person services, telemedicine, telehealth.

c. What direct services will be provided to citizens by the appropriation project?

Patients will receive direct medical care so that their sickle cell disease is actively managed,

d. Who is the target population served by this project? How many individuals are expected to be served?

The target population served by this project is elderly persons, persons with poor physical health, jobless persons, economically disadvantaged persons, at-risk youth, homeless, developmentally disabled, physically disabled, preschool students, grade school students,, high school students, university/college students, currently or formerly incarcerated persons, and individuals with sickle cell disease or sickle hemoglobinopathy. The individuals expected to be served are over 800.

e. What is the expected benefit or outcome of this project? What is the methodology by which this outcome will

be measured?

The expected benefit is to improve physical health by reducing sickle cell disease related emergency room visits, hospitalizations, ICU admissions and deaths. The method to measure is by claiming data Florida Health information exchange data from the Sickle Cell Disease Electronic Health Record HEDIS data from Health Plans.

f. What are the suggested penalties that the contracting agency may consider in addition to its standard penalties

for failing to meet deliverables or performance measures provided for the contract?

Failure to meet deliverables. Service provider shall be penalized by determined percentage with respect to any failure by service provider to meet the acceptance criteria for any deliveable as set forth in the applicable work agreement.

15. Requester Contact Information

-			
a. First Name	Lanetta	Last Name	Bronte-Hall
b. Organization	Foundation for Sickle Cell	Disease Res	search
c. E-mail Address	lbronte@fscdr.org		
d. Phone Number	(954)397-3251	Ext.	
16. Recipient Contact	Information		
a. Organization	Foundation of Sickle Cell	Disease Res	earch
b. Municipality and	d County Statewide		
c. Organization Ty	pe		
□For Profit Entity			
☑Non Profit 501(c	(3)		

□Non Profit 501(c)(4)

Local Entity



LFIR # 3049

□University or College

Other (please specify)

d. First Name	Lanetta	Last Name	Bronte-Hall
e. E-mail Address	lbronte@fscdr.org		
f. Phone Number	(954)397-3251		

17. Lobbyist Contact Information

a. Name	Yolanda Cash Jackson
b. Firm Name	Becker & Poliakoff PA
c. E-mail Address	yjackson@beckerlawyers.com
d. Phone Number	(954)985-4132